BioCentury | Apr 8, 2010
Distillery Therapeutics

Indication: Cancer

...includes testing the compound in animal models of cancer. Catena Pharmaceuticals Inc.'s LPA receptor antagonist, VPC51299...
BioCentury | Apr 13, 2009
Emerging Company Profile

Catena: Breaking the chain

...safer than VEGF inhibition and may more specifically target some diseases. Catena's lead molecule is VPC51299...
...receptors really don't have any overt negative side effects," he noted. IND-enabling preclinical testing on VPC51299...
...hopes to raise up to $5 million, which Mehr estimated would last about two years. VPC51299...
BioCentury | Oct 13, 2008
Company News

Catena, University of Virginia Patent Foundation deal

...IP covering VPC51299 and chemistries and methods related to GPCR antagonists that have antiangiogenic properties. VPC51299...
Items per page:
1 - 3 of 3